- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02355613
Comparative Evaluation of Two Different Radiosurgery
May 3, 2022 updated by: Michele Tedeschi, Istituto Clinico Humanitas
Comparative Evaluation of Two Different Radiosurgery Modalities in Brain Metastatic Patients From Several Solid Tumors
Randomized double arm phase III study to evaluate feasibility and safety of Gamma Knife radiosurgery and Linac Based (Edge) radiosurgery in brain metastatic patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a prospective double arm phase III study to evaluate cerebral side effects following radiosurgery delivered by Gamma Knife Perfexion and Linac Based EDGE.
In particular our primary objective is to evaluate rate of symptomatic radionecrosis from the two different modalities of radiosurgery.
Study Type
Interventional
Enrollment (Actual)
250
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
MI
-
Rozzano, MI, Italy, 20089
- Istituto Clinico Humanitas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 - 85 years
- 1 - 4 brain metastases
- Karnofsky performance status (KPS) ≥70
- RPA 1 or 2
- Histopathologically confirmation of primary solid tumor
- Estimated survival ≥ 3 months as GPA score
- Written informed consent
Exclusion Criteria:
- Prior WBRT
- Age > 85 years
- KPS < 70
- RPA 3
- Diagnosis of small cell lung cancer (SCLC) or Lymphoproliferative disease
- Use of Avastin for at least 2 months after radiosurgery
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Radiosurgery with Gamma Knife Perfexion
A single dose of 24 Gy at 50% isodose will be prescribed at metastases with diameter ≤ 20 mm, while a dose of 20 Gy at 50% isodose will be prescribed for metastases with diameter 21-30 mm
|
Gamma Knife Radiosurgery is a very precise form of therapeutic radiology.
Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions.
Minimum beam size is 4 mm.
This procedure is frame based.
|
Active Comparator: Linac-based Radiosurgery with EDGE
A single dose of 24 Gy will be prescribed at mean dose to PTV at metastases with diameter ≤ 20 mm, while a dose of 20 Gy will be prescribed for metastases with diameter 21-30 mm
|
EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment.
The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of symptomatic radionecrosis
Time Frame: two years
|
two years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Local Control of Brain Metastases
Time Frame: two years
|
two years
|
Disease Free survival
Time Frame: two years
|
two years
|
Overall survival
Time Frame: two years
|
two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marta Scorsetti, MD, Istituto Clinico Humanitas
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2014
Primary Completion (Actual)
June 1, 2020
Study Completion (Actual)
July 1, 2021
Study Registration Dates
First Submitted
January 13, 2015
First Submitted That Met QC Criteria
January 30, 2015
First Posted (Estimate)
February 4, 2015
Study Record Updates
Last Update Posted (Actual)
May 4, 2022
Last Update Submitted That Met QC Criteria
May 3, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1268
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastases to Brain
-
National Taiwan University HospitalUnknownMetastatic Malignant Neoplasm to BrainTaiwan
-
Lawson Health Research InstituteOntario Institute for Cancer ResearchCompletedMetastasis to Brain of Primary CancerCanada
-
Aposense Ltd.TerminatedMetastasis to Brain of Unknown Primary
-
Centre Francois BaclesseRoche Pharma AG; National Cancer Institute, France; Institut CurieCompletedMetastatic Malignant Neoplasm to BrainFrance
-
National Taiwan University HospitalRecruitingMetastatic Malignant Neoplasm to BrainTaiwan
-
Massachusetts General HospitalPfizerRecruiting
-
Medical University InnsbruckMarcel Seiz-Rosenhagen MD, PD; Meinhard Nevinny-Stickel MD, Prof.; Christian... and other collaboratorsUnknownMetastatic Malignant Neoplasm to the Adult BrainAustria
-
Hamilton Health Sciences CorporationOntario Clinical Oncology Group (OCOG); Juravinski Cancer Centre FoundationUnknownMetastatic Malignant Neoplasm to the Adult BrainCanada
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic Malignant Neoplasm to BrainUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedTumors Metastatic to BrainUnited States
Clinical Trials on Radiosurgery with Gamma Knife Perfexion
-
University of California, San FranciscoNorth American Gamma Knife ConsortiumTerminatedBrain MetastasesUnited States
-
University of California, San FranciscoNorth American Gamma Knife ConsortiumWithdrawnBrain MetastasesUnited States
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Swedish Medical CenterActive, not recruiting
-
Haukeland University HospitalCompleted
-
Yale UniversityTerminatedMelanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Brain Metastases | Gastrointestinal CancersUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
CancerCare ManitobaHealth Sciences Centre Foundation, ManitobaTerminatedNeoplasm MetastasesCanada
-
Elisabeth-TweeSteden ZiekenhuisZonMw: The Netherlands Organisation for Health Research and Development; Tilburg...CompletedNeoplasm MetastasesNetherlands
-
University of California, San FranciscoTerminated